Keros Therapeutics (NASDAQ:KROS) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report report published on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating on the stock.

Other research analysts have also issued reports about the company. Bank of America dropped their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Scotiabank started coverage on Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target for the company. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. Finally, Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $67.17 on Tuesday. The company has a 50-day simple moving average of $57.30 and a 200-day simple moving average of $51.99. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00. The firm has a market capitalization of $2.52 billion, a P/E ratio of -13.09 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm had revenue of $0.39 million for the quarter. During the same period in the prior year, the firm posted ($1.33) earnings per share. The business’s quarterly revenue was up 4750.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Keros Therapeutics will post -4.9 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

Several large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after acquiring an additional 251 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares in the last quarter. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares in the last quarter. Arizona State Retirement System raised its position in shares of Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after buying an additional 1,130 shares in the last quarter. Finally, American International Group Inc. lifted its position in Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after buying an additional 1,465 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.